Filing Flows › Comparisons › VTGN vs ROIV
Vistagen Therapeutics vs Roivant Sciences: VTGN and ROIV compared
Vistagen Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q1 FY27) against $1.4M for Roivant Sciences (Q1 FY27). Vistagen Therapeutics is growing faster (+505% against -34% a year earlier).
Where the money goes: VTGN and ROIV
Vistagen Therapeutics (VTGN) · Q1 FY27
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
Roivant Sciences (ROIV) · Q1 FY27
Roivant Sciences, Q1 FY27: revenue $1.4M (-34% year over year), net loss $291M, operating cash flow −$271M. The chart follows the revenue to costs, profit and cash.
| Vistagen Therapeutics (VTGN) | Roivant Sciences (ROIV) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q1 FY27 |
| Revenue | $1.5M | $1.4M |
| Revenue growth, Y/Y | +505% | -34% |
| Operating margin | -904.3% | n/m |
| Net earnings | −$13.0M | −$291M |
| Net margin | -882.8% | — |
| Operating cash flow | −$14.7M | −$271M |
Questions
Which is bigger, Vistagen Therapeutics or Roivant Sciences?
Vistagen Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q1 FY27) against $1.4M for Roivant Sciences (Q1 FY27).
Is Vistagen Therapeutics or Roivant Sciences growing faster?
Vistagen Therapeutics is growing faster (+505% against -34% a year earlier).
More: Vistagen Therapeutics earnings · how Vistagen Therapeutics makes money · Roivant Sciences earnings · how Roivant Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.